Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Covington
Colorcon
AstraZeneca
UBS
Merck
Express Scripts
Mallinckrodt

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021342

« Back to Dashboard

NDA 021342 describes LEVO-T, which is a drug marketed by Cediprof Inc and is included in one NDA. It is available from nineteen suppliers. There is one patent protecting this drug. Additional details are available on the LEVO-T profile page.

The generic ingredient in LEVO-T is levothyroxine sodium. There are ten drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 021342
Tradename:LEVO-T
Applicant:Cediprof Inc
Ingredient:levothyroxine sodium
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021342
Ingredient-typeThyroxine
Suppliers and Packaging for NDA: 021342
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LEVO-T levothyroxine sodium TABLET;ORAL 021342 NDA AUTHORIZED GENERIC Sandoz Inc. 0781-5180 0781-5180-10 1000 TABLET in 1 BOTTLE (0781-5180-10)
LEVO-T levothyroxine sodium TABLET;ORAL 021342 NDA AUTHORIZED GENERIC Sandoz Inc. 0781-5180 0781-5180-92 90 TABLET in 1 BOTTLE (0781-5180-92)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Approval Date:Mar 1, 2002TE:AB1,AB2,AB3RLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 30, 2020Product Flag?Substance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
QuintilesIMS
Julphar
Fish and Richardson
Cerilliant
McKesson
Healthtrust
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.